PMSG
2021-06-01
These layers have nothing better to do!
Lawsuits Filed Against FGEN, DNMR and WISH - Jakubowitz Law Pursues Shareholders Claims
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":119447746,"tweetId":"119447746","gmtCreate":1622561420085,"gmtModify":1631893704800,"author":{"id":3576810327636014,"idStr":"3576810327636014","authorId":3576810327636014,"authorIdStr":"3576810327636014","name":"PMSG","avatar":"https://static.tigerbbs.com/e55958327b4956d8b3f0ba1c4aaf9197","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>These layers have nothing better to do!</p></body></html>","htmlText":"<html><head></head><body><p>These layers have nothing better to do!</p></body></html>","text":"These layers have nothing better to do!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/119447746","repostId":2140663460,"repostType":2,"repost":{"id":"2140663460","pubTimestamp":1622552400,"share":"https://www.laohu8.com/m/news/2140663460?lang=&edition=full","pubTime":"2021-06-01 21:00","market":"us","language":"en","title":"Lawsuits Filed Against FGEN, DNMR and WISH - Jakubowitz Law Pursues Shareholders Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2140663460","media":"ACCESSWIRE","summary":"NEW YORK, NY / ACCESSWIRE / June 1, 2021 / Jakubowitz Law announces that securities fraud class acti","content":"<html><body><p><strong>NEW YORK, NY / ACCESSWIRE / June 1, 2021 /</strong> Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.</p>\n<p><u><strong><a href=\"https://laohu8.com/S/FGEN\">FibroGen, Inc</a>. (NASDAQ:FGEN)</strong></u></p>\n<p>CONTACT JAKUBOWITZ ABOUT <u><strong>FGEN</strong></u>:<br/>https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=16404&from=1</p>\n<p><strong>Class Period : October 18, 2017 - April 6, 2021</strong></p>\n<p><strong>Lead Plaintiff Deadline </strong>: June 11, 2021</p>\n<p>The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.</p>\n<p><u><strong><a href=\"https://laohu8.com/S/DNMR\">Danimer Scientific, Inc.</a> (NYSE:DNMR)</strong></u></p>\n<p>CONTACT JAKUBOWITZ ABOUT <u><strong>DNMR</strong></u>:<br/>https://claimyourloss.com/securities/danimer-scientific-inc-loss-submission-form/?id=16404&from=1</p>\n<p><strong>Class Period : October 5, 2020 - May 4, 2021</strong></p>\n<p><strong>Lead Plaintiff Deadline </strong>: July 13, 2021</p>\n<p>The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations' size and regulatory compliance; (iii) Defendants had overstated Nodax's biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.</p>\n<p><u><strong>Contextlogic Inc. (NASDAQ:WISH)</strong></u></p>\n<p>CONTACT JAKUBOWITZ ABOUT <u><strong>WISH</strong></u>:<br/>https://claimyourloss.com/securities/contextlogic-inc-loss-submission-form/?id=16404&from=1</p>\n<p><strong>This lawsuit is on behalf of investors who purchased WISH pursuant or traceable to the registration statement and prospectus issued in connection with ContextLogic's December 16, 2020 initial public stock offering or between December 16, 2020 and May 12, 2021.</strong></p>\n<p><strong>Lead Plaintiff Deadline </strong>: July 16, 2021</p>\n<p>In the registration statement and prospectus used to conduct the initial public offering and throughout the class period, defendants made materially false and misleading statements about the strength of ContextLogic's business operations and financial prospects by overstating its then-present monthly active users (\"MAUs\") and MAU growth trends.</p>\n<p><img height=\"278\" src=\"https://s1.yimg.com/uu/api/res/1.2/O14DCJMojM1Kz_zrpX48lw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/accesswire.ca/f1ecdb71f397ae601889e2b2d6c05583\" width=\"250\"/></p>\n<p>Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.</p>\n<p><strong>CONTACT:</strong></p>\n<p>JAKUBOWITZ LAW<br/>1140 Avenue of the Americas<br/>9th Floor<br/>New York, New York 10036<br/>T: (212) 867-4490<br/>F: (212) 537-5887</p>\n<p><strong>SOURCE: </strong>Jakubowitz Law</p>\n<br/>\n<br/>View source version on accesswire.com: \n<br/>\nhttps://www.accesswire.com/649890/Lawsuits-Filed-Against-FGEN-DNMR-and-WISH--Jakubowitz-Law-Pursues-Shareholders-Claims\n<br/>\n<br/>\n<img height=\"0\" src=\"https://www.accesswire.com/img.ashx?id=649890\" width=\"0\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuits Filed Against FGEN, DNMR and WISH - Jakubowitz Law Pursues Shareholders Claims</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuits Filed Against FGEN, DNMR and WISH - Jakubowitz Law Pursues Shareholders Claims\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:00 GMT+8 <a href=https://finance.yahoo.com/news/lawsuits-filed-against-fgen-dnmr-130000664.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, NY / ACCESSWIRE / June 1, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lawsuits-filed-against-fgen-dnmr-130000664.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/cyEQK9KmJWOSIAep12bK0w--~B/aD0xMDIxO3c9OTE4O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/fVES5gPVggJgH2S3tYNRLg--~B/aD0xMDIxO3c9OTE4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/accesswire.ca/f1ecdb71f397ae601889e2b2d6c05583","relate_stocks":{"DNMR":"Danimer Scientific, Inc.","FGEN":"FibroGen, Inc"},"source_url":"https://finance.yahoo.com/news/lawsuits-filed-against-fgen-dnmr-130000664.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2140663460","content_text":"NEW YORK, NY / ACCESSWIRE / June 1, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.\nFibroGen, Inc. (NASDAQ:FGEN)\nCONTACT JAKUBOWITZ ABOUT FGEN:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=16404&from=1\nClass Period : October 18, 2017 - April 6, 2021\nLead Plaintiff Deadline : June 11, 2021\nThe filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.\nDanimer Scientific, Inc. (NYSE:DNMR)\nCONTACT JAKUBOWITZ ABOUT DNMR:https://claimyourloss.com/securities/danimer-scientific-inc-loss-submission-form/?id=16404&from=1\nClass Period : October 5, 2020 - May 4, 2021\nLead Plaintiff Deadline : July 13, 2021\nThe filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations' size and regulatory compliance; (iii) Defendants had overstated Nodax's biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.\nContextlogic Inc. (NASDAQ:WISH)\nCONTACT JAKUBOWITZ ABOUT WISH:https://claimyourloss.com/securities/contextlogic-inc-loss-submission-form/?id=16404&from=1\nThis lawsuit is on behalf of investors who purchased WISH pursuant or traceable to the registration statement and prospectus issued in connection with ContextLogic's December 16, 2020 initial public stock offering or between December 16, 2020 and May 12, 2021.\nLead Plaintiff Deadline : July 16, 2021\nIn the registration statement and prospectus used to conduct the initial public offering and throughout the class period, defendants made materially false and misleading statements about the strength of ContextLogic's business operations and financial prospects by overstating its then-present monthly active users (\"MAUs\") and MAU growth trends.\n\nJakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.\nCONTACT:\nJAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887\nSOURCE: Jakubowitz Law\n\nView source version on accesswire.com: \n\nhttps://www.accesswire.com/649890/Lawsuits-Filed-Against-FGEN-DNMR-and-WISH--Jakubowitz-Law-Pursues-Shareholders-Claims","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":33,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/119447746"}
精彩评论